

(12) INTERNATIONAL PUBLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



26 APR 2005



(43) International Publication Date
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number
WO 2004/041165 A2

- (51) International Patent Classification⁷: **A61K** (74) Agent: KREISLER, Lewis, J.; Legal Department, 930 Clopper Road, Gaithersburg, MD 20878 (US).
- (21) International Application Number: PCT/US2003/034185 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 28 October 2003 (28.10.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/423,253 1 November 2002 (01.11.2002) US
- (71) Applicant (*for all designated States except US*): WELL-STAT THERAPEUTICS CORPORATION [US/US]; 930 Clopper Road, Gaithersburg, MD 20878 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): HODGE, Kirvin, I. [US/US]; 8115 Mississippi Road, Laurel, MD 20724 (US). SHARMA, Shalini [US/US]; 211 Bristol Downs Drive, Gaithersburg, MD 20878 (US). von Borstel, Reid W. [US/US]; 8310 Fox Run, Potomac, MD 20854 (US). WOLPE, Stephen, D. [US/US]; 18301 Clear Smoke Road, Boyds, MD 20841 (US).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

(57) Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

WO 2004/041165 A2

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

5

BACKGROUND OF THE INVENTION

Diabetes mellitus is a major cause of morbidity and mortality. Chronically elevated blood glucose leads to debilitating complications: nephropathy, often necessitating dialysis or renal transplant; peripheral neuropathy; retinopathy leading to blindness; ulceration of the legs and feet, leading to amputation; fatty liver disease, sometimes progressing to cirrhosis; and vulnerability to coronary artery disease and myocardial infarction.

There are two primary types of diabetes. Type I, or insulin-dependent diabetes mellitus (IDDM) is due to autoimmune destruction of insulin-producing beta cells in the pancreatic islets. The onset of this disease is usually in childhood or adolescence. Treatment consists primarily of multiple daily injections of insulin, combined with frequent testing of blood glucose levels to guide adjustment of insulin doses, because excess insulin can cause hypoglycemia and consequent impairment of brain and other functions.

Type II, or noninsulin-dependent diabetes mellitus (NIDDM) typically develops in adulthood. NIDDM is associated with resistance of glucose-utilizing tissues like adipose tissue, muscle, and liver, to the actions of insulin. Initially, the pancreatic islet beta cells compensate by secreting excess insulin. Eventual islet failure results in decompensation and chronic hyperglycemia. Conversely, moderate islet insufficiency can precede or coincide with peripheral insulin resistance. There are several classes of drugs that are useful for treatment of NIDDM: 1) insulin releasers, which directly stimulate insulin release, carrying the risk of hypoglycemia; 2) prandial insulin releasers, which potentiate glucose-induced insulin secretion, and must be taken before each meal; 3) biguanides, including metformin, which attenuate hepatic gluconeogenesis (which is paradoxically elevated in diabetes); 4) insulin sensitizers, for example the thiazolidinedione derivatives rosiglitazone and pioglitazone, which improve peripheral responsiveness to insulin, but which have side effects like weight

5 gain, edema, and occasional liver toxicity; 5) insulin injections, which are often necessary in the later stages of NIDDM when the islets have failed under chronic hyperstimulation.

10 Insulin resistance can also occur without marked hyperglycemia, and is generally associated with atherosclerosis, obesity, hyperlipidemia, and essential hypertension. This cluster of abnormalities constitutes the "metabolic syndrome" or "insulin resistance syndrome". Insulin resistance is also associated with fatty liver, which can progress to chronic inflammation (NASH; "nonalcoholic steatohepatitis"), fibrosis, and cirrhosis. Cumulatively, insulin resistance syndromes, including but not limited to diabetes, underlie many of the major causes of morbidity and death of people over
15 age 40.

Despite the existence of such drugs, diabetes remains a major and growing public health problem. Late stage complications of diabetes consume a large proportion of
20 national health care resources. There is a need for new orally active therapeutic agents which effectively address the primary defects of insulin resistance and islet failure with fewer or milder side effects than existing drugs.

Currently there are no safe and effective treatments for fatty liver disease. Therefore
25 such a treatment would be of value in treating this condition.

SUMMARY OF THE INVENTION

This invention provides the use of a biologically active agent as set forth below in the
30 manufacture of a medicament for the treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis. This invention also provides methods of treating a mammalian subject with insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis comprising administering to
35 the subject an effective amount of a biologically active agent in accordance with this invention. This invention also provides a pharmaceutical composition comprising a biologically active agent of this invention and a pharmaceutically acceptable carrier.

- 5 It is believed that the biologically active agents of this invention will have activity in one or more of the biological activity assays described below, which are established animal models of human diabetes and insulin resistance syndrome. Therefore such agents would be useful in the treatment of diabetes and insulin resistance syndrome.

10 DETAILED DESCRIPTION OF THE INVENTION

As used herein the transitional term "comprising" is open-ended. A claim utilizing this term can contain elements in addition to those recited in such claim.

- 15 The biologically active agent that is utilized in accordance with the uses, methods of treatment and pharmaceutical compositions described above is selected from the following compounds and their pharmaceutically acceptable salts:
- 4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid;
Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate;
- 20 Ethyl 4-(4-cyclohexylmethoxyphenyl)-4-oxobutanoate;
4-(3-chloro-4-cyclopropylmethoxyphenyl)-4-oxobutanoic acid;
Ethyl 3-(4-benzyloxyphenyl)-3-oxopropanoate;
Ethyl 3-(3-benzyloxyphenyl)-3-oxopropanoate;
Ethyl 3-(2-benzyloxyphenyl)-3-oxopropanoate;
- 25 Methyl 3-(3-(2,6-dichlorobenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(4-(4-chlorobenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(3-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(2-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(2-(2-methoxybenzyloxy)phenyl)-3-oxopropanoate;
- 30 Ethyl 3-(2-(3-methoxybenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(4-benzyloxy-3-chlorophenyl)-3-oxopropanoate;
Ethyl 3-(4-benzyloxy-3-methoxyphenyl)-3-oxopropanoate; and
Ethyl 3-(3-benzyloxy-4-methoxyphenyl)-3-oxopropanoate.
- 35 This invention provides a method for treating a mammalian subject with a condition selected from the group consisting of insulin resistance syndrome and diabetes (both primary essential diabetes such as Type I Diabetes or Type II Diabetes and secondary nonessential diabetes), comprising administering to the subject an amount of a

5 biologically active agent as described herein effective to treat the condition. In accordance with the method of this invention a symptom of diabetes or the chance of developing a symptom of diabetes, such as atherosclerosis, obesity, hypertension, hyperlipidemia, fatty liver disease, nephropathy, neuropathy, retinopathy, foot ulceration and cataracts, each such symptom being associated with diabetes, can be
10 reduced. This invention also provides a method for treating hyperlipidemia comprising administering to the subject an amount of a biologically active agent as described herein effective to treat the condition. This invention also provides a method for treating cachexia comprising administering to the subject an amount of a biologically active agent as described herein effective to treat the cachexia. This
15 invention also provides a method for treating obesity comprising administering to the subject an amount of a biologically active agent as described herein effective to treat the condition. This invention also provides a method for treating a condition selected from atherosclerosis or arteriosclerosis comprising administering to the subject an amount of a biologically active agent as described herein effective to treat the
20 condition. The active agents of this invention are effective to treat hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis or arteriosclerosis whether or not the subject has diabetes or insulin resistance syndrome. The agent can be administered by any conventional route of systemic administration. Preferably the agent is administered orally. Other routes of administration that can be used in
25 accordance with this invention include rectally, parenterally, by injection (e.g. intravenous, subcutaneous, intramuscular or intraperitoneal injection), or nasally.

Many of the diseases or disorders that are addressed by the compounds of the invention fall into two broad categories: Insulin resistance syndromes and
30 consequences of chronic hyperglycemia. Dysregulation of fuel metabolism, especially insulin resistance, which can occur in the absence of diabetes (persistent hyperglycemia) per se, is associated with a variety of symptoms, including hyperlipidemia, atherosclerosis, obesity, essential hypertension, fatty liver disease (NASH; nonalcoholic steatohepatitis), and, especially in the context of cancer or
35 systemic inflammatory disease, cachexia. Cachexia can also occur in the context of Type I Diabetes or late-stage Type II Diabetes. By improving tissue fuel metabolism, active agents of the invention are useful for preventing or ameliorating diseases and symptoms associated with insulin resistance, as is demonstrated in animals in the

5 Examples. While a cluster of signs and symptoms associated with insulin resistance may coexist in an individual patient, in many cases only one symptom may dominate, due to individual differences in vulnerability of the many physiological systems affected by insulin resistance. Nonetheless, since insulin resistance is a major contributor to many disease conditions, drugs which address this cellular and
10 molecular defect are useful for prevention or amelioration of virtually any symptom in any organ system that may be due to, or exacerbated by, insulin resistance.

When insulin resistance and concurrent inadequate insulin production by pancreatic islets are sufficiently severe, chronic hyperglycemia occurs, defining the onset of
15 Type II diabetes mellitus (NIDDM). In addition to the metabolic disorders related to insulin resistance indicated above, disease symptoms secondary to hyperglycemia also occur in patients with NIDDM. These include nephropathy, peripheral neuropathy, retinopathy, microvascular disease, ulceration of the extremities, and consequences of nonenzymatic glycosylation of proteins, e.g. damage to collagen and other connective
20 tissues. Attenuation of hyperglycemia reduces the rate of onset and severity of these consequences of diabetes. Because, as is demonstrated in the Examples, active agents and compositions of the invention help to reduce hyperglycemia in diabetes, they are useful for prevention and amelioration of complications of chronic hyperglycemia.

25 Both human and non-human mammalian subjects can be treated in accordance with the treatment method of this invention. The optimal dose of a particular active agent of the invention for a particular subject can be determined in the clinical setting by a skilled clinician. In the case of oral administration to a human for treatment of disorders related to insulin resistance, diabetes, hyperlipidemia, fatty liver disease, cachexia or obesity the agent is generally administered in a daily dose of from 1 mg to
30 3000 mg, administered once or twice per day. In more specific embodiments the daily dose in humans is from 1 mg to 400 mg, or from 20 mg to 200, administered once or twice per day. In the case of oral administration to a mouse the agent is generally administered in a daily dose from 1 to 300 mg of the agent per kilogram of
35 body weight. Active agents of the invention are used as monotherapy in diabetes or insulin resistance syndrome, or in combination with one or more other drugs with utility in these types of diseases, e.g. insulin releasing agents, prandial insulin releasers, biguanides, or insulin itself. Such additional drugs are administered in

5 accord with standard clinical practice. In some cases, agents of the invention will improve the efficacy of other classes of drugs, permitting lower (and therefore less toxic) doses of such agents to be administered to patients with satisfactory therapeutic results. Established safe and effective dose ranges in humans for representative compounds are: metformin 500 to 2550 mg/day; glyburide 1.25 to 20 mg/day;
10 GLUCOVANCE (combined formulation of metformin and glyburide) 1.25 to 20 mg/day glyburide and 250 to 2000 mg/day metformin; atorvastatin 10 to 80 mg/day; lovastatin 10 to 80 mg/day; pravastatin 10 to 40 mg/day; and simvastatin 5-80 mg/day; clofibrate 2000 mg/day; gemfibrozil 1200 to 2400 mg/day, rosiglitazone 4 to 8 mg/day; pioglitazone 15 to 45 mg/day; acarbose 75-300 mg/day; repaglinide 0.5 to
15 16 mg/day.

Type I Diabetes Mellitus: A patient with Type I diabetes manages their disease primarily by self-administration of one to several doses of insulin per day, with frequent monitoring blood glucose to permit appropriate adjustment of the dose and
20 timing of insulin administration. Chronic hyperglycemia leads to complications such as nephropathy, neuropathy, retinopathy, foot ulceration, and early mortality; hypoglycemia due to excessive insulin dosing can cause cognitive dysfunction or unconsciousness. A patient with Type I diabetes is treated with 1 to 400 mg/day of an active agent of this invention in tablet or capsule form either as a single or a divided
25 dose. The anticipated effect will be a reduction in the dose or frequency of administration of insulin required to maintain blood glucose in a satisfactory range, and a reduced incidence and severity of hypoglycemic episodes. Clinical outcome is monitored by measurement of blood glucose and glycosylated hemoglobin (an index of adequacy of glycemic control integrated over a period of several months), as well
30 as by reduced incidence and severity of typical complications of diabetes. A biologically active agent of this invention can be administered in conjunction with islet transplantation to help maintain the anti-diabetic efficacy of the islet transplant.

Type II Diabetes Mellitus: A typical patient with Type II diabetes (NIDDM) manages
35 their disease by programs of diet and exercise as well as by taking medications such as metformin, glyburide, repaglinide, rosiglitazone, or acarbose, all of which provide some improvement in glycemic control in some patients, but none of which are free of side effects or eventual treatment failure due to disease progression. Islet failure

- 5 occurs over time in patients with NIDDM, necessitating insulin injections in a large fraction of patients. It is anticipated that daily treatment with an active agent of the invention (with or without additional classes of antidiabetic medication) will improve glycemic control, reduce the rate of islet failure, and reduce the incidence and severity of typical symptoms of diabetes. In addition, active agents of the invention will
- 10 reduce elevated serum triglycerides and fatty acids, thereby reducing the risk of cardiovascular disease, a major cause of death of diabetic patients. As is the case for all other therapeutic agents for diabetes, dose optimization is done in individual patients according to need, clinical effect, and susceptibility to side effects.
- 15 **Hyperlipidemia:** Elevated triglyceride and free fatty acid levels in blood affect a substantial fraction of the population and are an important risk factor for atherosclerosis and myocardial infarction. Active agents of the invention are useful for reducing circulating triglycerides and free fatty acids in hyperlipidemic patients. Hyperlipidemic patients often also have elevated blood cholesterol levels, which also
- 20 increase the risk of cardiovascular disease. Cholesterol-lowering drugs such as HMG-CoA reductase inhibitors ("statins") can be administered to hyperlipidemic patients in addition to agents of the invention, optionally incorporated into the same pharmaceutical composition.
- 25 **Fatty Liver Disease:** A substantial fraction of the population is affected by fatty liver disease, also known as nonalcoholic steatohepatitis (NASH); NASH is often associated with obesity and diabetes. Hepatic steatosis, the presence of droplets of triglycerides with hepatocytes, predisposes the liver to chronic inflammation (detected in biopsy samples as infiltration of inflammatory leukocytes), which can lead to
- 30 fibrosis and cirrhosis. Fatty liver disease is generally detected by observation of elevated serum levels of liver-specific enzymes such as the transaminases ALT and AST, which serve as indices of hepatocyte injury, as well as by presentation of symptoms which include fatigue and pain in the region of the liver, though definitive diagnosis often requires a biopsy. The anticipated benefit is a reduction in liver
- 35 inflammation and fat content, resulting in attenuation, halting, or reversal of the progression of NASH toward fibrosis and cirrhosis.

5 This invention provides a pharmaceutical composition comprising a biologically active agent as described herein and a pharmaceutically acceptable carrier. Further embodiments of the pharmaceutical composition of this invention comprise any one of the embodiments of the biologically active agents described above. In the interest of avoiding unnecessary redundancy, each such agent and group of agents is not being
10 repeated, but they are incorporated into this description of pharmaceutical compositions as if they were repeated.

Preferably the composition is adapted for oral administration, e.g. in the form of a tablet, coated tablet, dragee, hard or soft gelatin capsule, solution, emulsion or
15 suspension. In general the oral composition will comprise from 1 mg to 400 mg of such agent. It is convenient for the subject to swallow one or two tablets, coated tablets, dragees, or gelatin capsules per day. However the composition can also be adapted for administration by any other conventional means of systemic administration including rectally, e.g. in the form of suppositories, parenterally, e.g. in
20 the form of injection solutions, or nasally.

The biologically active compounds can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical compositions. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like
25 can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatin capsules. Suitable carriers for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active ingredient no carriers are, however, usually required in the case of soft gelatin capsules, other than the soft gelatin itself. Suitable carriers for the production
30 of solutions and syrups are, for example, water, polyols, glycerol, vegetable oils and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semiliquid or liquid polyols and the like.

The pharmaceutical compositions can, moreover, contain preservatives, solubilizers,
35 stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, coating agents or antioxidants. They can also contain still other therapeutically valuable substances, particularly antidiabetic or hypolipidemic agents that act through mechanisms other than those underlying the

5 effects of the compounds of the invention. Agents which can advantageously be
combined with compounds of the invention in a single formulation include but are not
limited to biguanides such as metformin, insulin releasing agents such as the
sulfonylurea insulin releaser glyburide and other sulfonylurea insulin releasers,
10 cholesterol-lowering drugs such as the "statin" HMG-CoA reductase inhibitors such
as atrovastatin, lovastatin, pravastatin and simvastatin, PPAR-alpha agonists such as
clofibrate and gemfibrozil, PPAR-gamma agonists such as thiazolidinediones (e.g.
rosiglitazone and pioglitazone, alpha-glucosidase inhibitors such as acarbose (which
inhibit starch digestion), and prandial insulin releasers such as repaglinide. The
15 amounts of complementary agents combined with compounds of the invention in
single formulations are in accord with the doses used in standard clinical practice.
Established safe and effective dose ranges for certain representative compounds are
set forth above.

The compounds that are listed above are known compounds. A partial listing of
20 references to such compounds in the patent and technical literature is as follows:

4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid :

Japanese Kokai No. 55015460.

25 Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate :

Von Wacek, et al., Monatsh. Chem. (1966), 97 (3), 744-753.

Ethyl 4-(4-cyclohexylmethoxyphenyl)-4-oxobutanoate :

Japanese Kokai No. 61040270.

30

4-(3-chloro-4-cyclopropylmethoxyphenyl)-4-oxobutanoic acid :

Japanese Kokai No. 55015460.

Ethyl 3-(4-benzyloxyphenyl)-3-oxopropanoate :

35 WO 02/59077; and Winters, et al., Eur. J. Med. Chem. -- Chim. Ther. (1984), 19 (3),
215-218.

- 5 Ethyl 3-(3-benzyloxyphenyl)-3-oxopropanoate :
WO 02/59077.

- Ethyl 3-(2-benzyloxyphenyl)-3-oxopropanoate :
Karche et al., Journal of Organic Chemistry (2001), 66(19), 6323-6332; and Charlton,
10 et al., J. Heterocycl. Chem. (1980), 17 (3), 593-594.

Methyl 3-(3-(2,6-dichlorobenzyloxy)phenyl)-3-oxopropanoate :
WO 02/02119.

- 15 Ethyl 3-(4-(4-chlorobenzyloxy)phenyl)-3-oxopropanoate :
Japanese Kokai No. 52025734.

- Ethyl 3-(3-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate :
WO 01/81340.

- 20 Ethyl 3-(2-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(2-(2-methoxybenzyloxy)phenyl)-3-oxopropanoate; and
Ethyl 3-(2-(3-methoxybenzyloxy)phenyl)-3-oxopropanoate :
Karche et al., Journal of Organic Chemistry (2001), 66(19), 6323-6332.

- 25 Ethyl 3-(4-benzyloxy-3-chlorophenyl)-3-oxopropanoate :
Fadnavis, et al., Tetrahedron: Asymmetry (1997), 8(24), 4003-4006.

- Ethyl 3-(4-benzyloxy-3-methoxyphenyl)-3-oxopropanoate :
30 Wu, et al., Huaxue Yanjiu Yu Yingyong (1997) , 9(6), 595-599; and
Herbert, et al., J. Chem. Soc., Perkin Trans. 1 (1984), (4), 825-831.

- Ethyl 3-(3-benzyloxy-4-methoxyphenyl)-3-oxopropanoate :
Bose, et al., Phytochemistry (1991), 30(7), 2438-2439; and
35 Arnoldi, et al. J. Agric. Food Chem. (1986), 34 (2), 339-344.

In addition, all of these compounds can be synthesized as described in
WO 02/100341.

- 5 The invention will be better understood by reference to the following examples which illustrate but do not limit the invention described herein.

EXAMPLES

- 10 EXAMPLE A. Improvement of metabolic abnormalities in insulin-dependent diabetes

Streptozotocin (STZ) is a toxin that selectively destroys insulin-producing pancreatic beta cells, and is widely used to induce insulin-dependent diabetes in experimental
15 animals.

Female Balb/C mice (8 weeks old; 18-20 grams body weight) are treated with streptozotocin (STZ) (50 mg/kg i.p. on each of five consecutive days). Fourteen days after the last dose of STZ, blood glucose is measured to verify that the animals are
20 diabetic, and the mice are divided into two groups of 5 animals each, one group receiving a compound of the invention (250 mg/kg) daily by oral gavage, and the other receiving vehicle (0.75% hydroxypropylmethylcellulose, a suspending agent, in water). A group of nondiabetic mice from the same cohort that did not receive STZ is also monitored. Blood samples are taken periodically for determination of blood
25 glucose concentrations, and body weights are also recorded.

After several weeks of treatment, blood glucose concentrations in mice treated orally with the compound of the invention and in vehicle-treated control animals are measured. A blood glucose concentration beginning to decrease toward baseline is
30 considered a positive result, whereas blood glucose in the vehicle-treated control animals is expected to continue to rise. Body weights and blood glucose, triglyceride and cholesterol concentrations 14 weeks after the beginning of drug treatment are measured.

- 35 EXAMPLE B: Improved survival of mice with lethal insulin-dependent diabetes

Female Balb/C mice (14 weeks old) are treated with a single dose of streptozotocin (175 mg/kg i.p.) to induce severe insulin-dependent diabetes. Seven days later, mice

- 5 are divided into three treatment groups: A compound of the invention, pioglitazone, and vehicle. Mice are treated daily via oral gavage, and survival is monitored over time.

EXAMPLE C: Reduction of mortality in severe insulin-dependent diabetes

10

- Female balb/C mice (19 wks of age at start of experiment) are challenged with multiple high doses of STZ (75 mg/kg i.p. on 5 consecutive days). Animals are then divided in two groups (20 mice / group) matched for severity of diabetes. Four days after the last dose of STZ, treatments are initiated. One group receives Vehicle (0.4 ml of 0.75% HPMC, p.o.), and the other group receives a compound of the invention orally (30 mg/kg/day). After three weeks of daily treatment, cumulative mortality in the two groups is recorded.
- 15

EXAMPLE D: Reduction in the incidence of spontaneous diabetes and mortality in

20 NOD mice

- A substantial proportion of NOD ("non-obese diabetic") mice develop insulin-dependent diabetes as a consequence of spontaneous autoimmune destruction of pancreatic islet cells. Two groups of 20 NOD mice (6 weeks old) are treated daily with either oral Vehicle (0.4 ml of 0.75% hydroxypropyl methylcellulose in water; HPMC) or a compound of the invention (200 mg/kg/day) suspended in HPMC. The incidence of mortality due to spontaneous development of severe insulin-dependent diabetes is monitored over a period of seven months.
- 25

- 30 EXAMPLE E. Reduction in hyperglycemia and hyperlipidemia, and amelioration of fatty liver disease in ob/ob obese diabetic mice

- Ob/ob mice have a defect in the gene for leptin, a protein involved in appetite regulation and energy metabolism, and are hyperphagic, obese, and insulin resistant. They develop hyperglycemia and fatty liver.
- 35

- 5 Male lean (ob/+ heterozygote) and obese (ob/ob homozygote) C57BL/6 mice approximately 8 weeks of age are obtained from Jackson Labs (Bar Harbor, ME) and randomly assigned into groups of 5 animals such that body weights and blood glucose concentrations are similar between groups. All animals are maintained under the control of temperature (23 C), relative humidity (50 ± 5 %) and light (7:00 – 19:00),
10 and allowed free access to water and laboratory chow (Formulab Diet 5008, Quality Lab Products, Elkridge, MD). Blood glucose is routinely determined with glucose test strips and a Glucometer Elite XL device (Bayer Corporation). At selected time points, blood samples (~100 microliters) are obtained with a heparinized capillary tube via the retro-orbital sinus for serum chemistry analysis. Serum chemistry
15 (glucose, triglycerides, cholesterol, BUN, creatinine, AST, ALT, SDH, CPK and free fatty acids) analyses are performed on a Hitachi 717 Analyzer, and plasma insulin and pancreatic insulin are measured by an electrochemiluminescent immunoassay (Origen Analyzer, Igen, Inc., Gaithersburg, MD).
- 20 Groups of ob/ob mice are divided into treatment cohorts as indicated below, and given daily oral doses of a compound of the invention (10, 30, 100, 150 or 300 mg), rosiglitazone (1, 3, 10 or 30 mg), or pioglitazone (30 or 100 mg). The latter two compounds are insulin-sensitizing drugs used in the treatment of human patients with non-insulin dependent diabetes mellitus, and are used as comparators for efficacy and
25 safety of compounds of the invention. The dose ranges of compounds in this experiment is chosen to include both suboptimal and potentially supraoptimal doses.
- Ob/ob mice develop chronic inflammatory fatty liver disease and are considered to be an animal model for nonalcoholic steatohepatitis (NASH), a condition which can lead
30 toward progressive cirrhosis and liver dysfunction. In NASH, fat accumulation increases the susceptibility of the liver to inflammatory injury. One characteristic sign of NASH in patients is, in the absence of viral infection or alcoholism, elevated levels in serum of enzymes that are released from damaged hepatocytes, e.g. alanine aminotransferase (ALT), aspartate aminotransferase (AST), and sorbitol
35 dehydrogenase (SDH). These enzymes are elevated in ob/ob mice as a consequence of fatty liver and secondary inflammation.

5 **EXAMPLE F: Acute hypoglycemic effects of compounds of the invention in diabetic mice: Experiment 1.**

Compounds of the invention display acute antihyperglycemic activity in animals with non insulin-dependent diabetes.

10

Male ob/ob diabetic mice are randomized into groups of five animals each. Body weights are about 50 –55 g and blood glucose is approximately 300 mg/dL in the fed state. A single oral dose of a test substance suspended in 0.5% carboxymethylcellulose vehicle is administered by gavage. Blood glucose is measured in blood droplets obtained by nicking a tail vein with a razor using glucometer test strips and a Glucometer Elite XL device (Bayer) at 0, 0.5, 2, 4, 6 and 18 hours after the initial dosing. A 10% reduction in blood glucose versus oral vehicle is considered a positive screening result. Blood glucose reductions are generally expected to be maximal at 6 hours after drug administration.

20

EXAMPLE G: Acute hypoglycemic effects of compounds of the invention in diabetic mice: Expt 2

Compounds of the invention display acute antihyperglycemic activity in animals with noninsulin-dependent diabetes.

25

Male ob/ob mice (50-55 grams; blood glucose ~300 mg/dL) are divided into groups of five animals each, and given a single oral dose of test drug (250 mg/kg) suspended in 0.5% carboxymethylcellulose vehicle; a control group received oral vehicle alone. Six hours after oral administration of test drugs or vehicle (control), blood samples are obtained from a tail vein and glucose content is determined with a glucometer.

30

EXAMPLE H: Antidiabetic effects of compounds of the invention in db/db mice

Db/db mice have a defect in leptin signaling, leading to hyperphagia, obesity and diabetes. Moreover, unlike ob/ob mice which have relatively robust islets, their insulin-producing pancreatic islet cells undergo failure during chronic hyperglycemia, so that they transition from hyperinsulinemia (associated with peripheral insulin resistance) to hypoinsulinemic diabetes.

35

5 Male db/db mice are given daily oral treatments with vehicle (0.75% hydroxypropylmethylcellulose), a compound of the invention (150 mg/kg), or pioglitazone (100 mg/kg). Blood samples are obtained via the retro-orbital sinus for serum chemistry analysis, or via the tail vein for glucose measurement with a test strip and glucometer. The dose of pioglitazone used in this experiment was reported in the
10 literature to be a maximally-effective dose for treatment of db/db mice (Shimaya et al. (2000), Metabolism 49:411-7).

In a second experiment in db/db mice, antidiabetic activity of a compound of the invention (150 mg/kg) is compared with that of rosiglitazone (20 mg/kg). After 8
15 weeks of treatment, blood glucose and triglycerides are measured. significantly lower in animals treated with either Compound BI or rosiglitazone, compared to vehicle-treated controls. The rosiglitazone dose used in this study was reported in published literature as the optimum dose for late stage db/db mice (Lenhard et al., (1999) Diabetologia 42:545-54). Groups consist of 6-8 mice each.

20

EXAMPLE I: Antidiabetic effects of compounds of the invention in db/db mice.

db/db mice have a defect in leptin signaling, leading to hyperphagia, obesity and diabetes. Moreover, unlike ob/ob mice on a C57BL/6J background, db/db mice on a
25 C57BL/KS background undergo failure of their insulin-producing pancreatic islet β cells, resulting in progression from hyperinsulinemia (associated with peripheral insulin resistance) to hypoinsulinemic diabetes.

Male obese (db/db homozygote) C57BL/Ksola mice approximately 8 weeks of age,
30 are obtained from Jackson Labs (Bar Harbor, ME) and randomly assigned into groups of 5 – 7 animals such that the body weights (50 – 55 g) and serum glucose levels (≥ 300 mg/dl in fed state) are similar between groups; male lean (db/+ heterozygote) mice serve as cohort controls. A minimum of 7 days is allowed for adaptation after arrival. All animals are maintained under controlled temperature (23 °C), relative
35 humidity (50 ± 5 %) and light (7:00 – 19:00), and allowed free access to standard chow (Formulab Diet 5008, Quality Lab Products, Elkridge, MD) and water.

- 5 Treatment cohorts are given daily oral doses of (1% hydroxypropylmethylcellulose) or a compound of the invention (100 mg/kg) for 2 weeks. At the end of the treatment period 100 μ l of venous blood is withdrawn in a heparinized capillary tube from the retro-orbital sinus of db/db mice for serum chemistry analysis.
- 10 Effects of compounds of the invention on nonfasting blood glucose and on serum triglycerides and free fatty acids are measured.

EXAMPLE J: Attenuation of cataractogenesis of compounds of the invention in Zucker diabetic fatty (ZDF) rats

15

Cataracts are one of the leading causes of progressive vision decline and blindness associated with ageing and diabetes, and the Zucker diabetic fatty (ZDF) model has many similarities with human cataractogenesis, including biochemical changes and oxidative stress in the lens. These rats, however, undergo cataractogenesis typically

20 between 14–16 weeks of age.

- Male ZDF rats and their aged-match Zucker lean (ZL) counterparts (fa/+ or +/+) are obtained from Genetic Models, Inc. (Indianapolis, IN) aged 12 weeks and acclimatized for 1 week prior to study. All animals are maintained under controlled
- 25 temperature (23 °C), relative humidity (50 ± 5 %) and light (7:00 – 19:00), and allowed free access to standard chow (Formulab Diet 5008, Quality Lab Products, Elkridge, MD) and tap water ad libitum. Treatment cohorts are given a daily oral dose of vehicle and 100 mg/kg of a compound of the invention for 10 weeks. Body weights and blood glucose are routinely determined (once a week, usually around
- 30 10:00 A.M.) from tail bleeds with glucose test strips and a Glucometer Elite XL device (Bayer Corporation). At the end of the treatment period 100 μ l of venous blood is collected (usually 10:00 A.M.) in a heparinized tube from the tail vein for serum chemistry analysis (Anilytics, Inc., Gaithersburg, MD). Serum chemistry (glucose (GL), triglycerides (TG), aspartate aminotransferase (AST), alanine aminotransferase (ALT), sorbitol dehydrogenase (SDH), and free fatty acids (FFA)) analyses are
- 35 performed on a Hitachi 717 Analyzer (Anilytics, Inc., Gaithersburg, MD). Plasma insulin is measured by an electrochemiluminescent immunoassay, ECL (Origen Analyzer, Igen, Inc., Gaithersburg, MD). The animals are sacrificed and tissues and/or

5 organs (lens and liver) are extirpated, weighed (wet weight) and processed for biochemical analyses. Malondialdehyde (MDA), a major product of lipid peroxidation was assayed in lenses according to Ohkawa et al (1979), Analytical Biochem 95, 351-358).

10

EXAMPLE K: Lowering of circulating triglycerides, free fatty acids, insulin and leptin in high fat-fed C57Bl/6J mice

The high fat-fed mouse is a model for the hypertriglyceridemia and high circulating
15 fatty acid levels, and the insulin and leptin resistance that are found in people at risk for and with obesity, diabetes, cardiovascular disease and other disorders. Male C57Bl/6J mice, approximately 8 weeks of age, are randomly assigned into groups of 6 animals. They are maintained under controlled temperature (23 °C), relative humidity (50 ± 5 %) and light (7:00 – 19:00), and allowed free access to food and water ad
20 libitum. Mice are fed a high-fat diet (diet number D12451, containing 45% of calories as fat (Research Diets, New Brunswick, NJ)) for 6 weeks. After the 6 weeks, groups of mice received either vehicle (hydroxymethylcellulose), a compound of the invention (10 mg/kg, 30 mg/kg, or 100 mg/kg) Wy14,643 (10 mg/kg, 30 mg/kg, or 100 mg/kg) or rosiglitazone (1mg/kg, 3 mg/kg, 10 mg/kg, or 100 mg/kg) by oral
25 gavage for an additional 4 weeks while continuing on the high-fat diet. Plasma chemistries (Anilytics, Inc., Gaithersburg, MD) are assayed after 2 weeks of drug treatments. Plasma serum insulin and leptin are measured by an electrochemiluminescent immunoassay (Origen Analyzer, Igen, Inc., Gaithersburg, MD) after 4 weeks of drug treatments.

30

EXAMPLE L: Lowering of circulating triglycerides, free fatty acids, insulin and leptin in high fat-fed Sprague-Dawley rats

The high fat-fed rat is a model for insulin and leptin resistance. Sprague-Dawley rats
35 have an intact leptin system and respond to a high fat diet with hyperinsulinemia due to a downregulation of the normal insulin response in peripheral tissues such as liver, adipose tissue and muscle

- 5 Male Sprague-Dawley rats, approximately 17 weeks of age, are obtained from Jackson Labs (Bar Harbor, ME) and randomly assigned into groups of 5 – 7 animals; the body weights are similar between groups. All animals are maintained in a temperature-controlled (25°C) facility with a strict 12 h light/dark cycle and are given free access to water and food. Rats are fed a high-fat diet (diet number D12451
- 10 (containing 45 % of calories as fat), Research Diets, New Brunswick, NJ) for one month prior to drug treatment.

- Groups of 6 Sprague-Dawley rats are treated with a single daily dose of vehicle (hydroxymethylcellulose), a compound of the invention (10, 30 and 100 mg/kg), or
- 15 rosiglitazone (3 mg/kg) for 6 weeks while maintaining the high-fat diet. Blood samples (~100 µl) are obtained via the tail vein for serum chemistry analysis.

CLAIMS

What is claimed is:

1. Use of a biologically active agent in the manufacture of a medicament for treatment of a condition selected from the group consisting of insulin resistance syndrome and diabetes including Type I Diabetes and Type II Diabetes; or for the treatment or reduction in the chance of developing atherosclerosis, arteriosclerosis, obesity, hypertension, hyperlipidemia, fatty liver disease, nephropathy, neuropathy, retinopathy, foot ulceration or cataracts associated with diabetes; or for the treatment of a condition selected from the group consisting of hyperlipidemia, cachexia, and obesity;

wherein the agent is selected from the group consisting of:

4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid;
Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate;
Ethyl 4-(4-cyclohexylmethoxyphenyl)-4-oxobutanoate;
4-(3-chloro-4-cyclopropylmethoxyphenyl)-4-oxobutanoic acid;
Ethyl 3-(4-benzyloxyphenyl)-3-oxopropanoate;
Ethyl 3-(3-benzyloxyphenyl)-3-oxopropanoate;
Ethyl 3-(2-benzyloxyphenyl)-3-oxopropanoate;
Methyl 3-(3-(2,6-dichlorobenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(4-(4-chlorobenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(3-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(2-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(2-(2-methoxybenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(2-(3-methoxybenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(4-benzyloxy-3-chlorophenyl)-3-oxopropanoate;
Ethyl 3-(4-benzyloxy-3-methoxyphenyl)-3-oxopropanoate;
Ethyl 3-(3-benzyloxy-4-methoxyphenyl)-3-oxopropanoate;

and pharmaceutically acceptable salts thereof.

2. A method for treating a mammalian subject with a condition selected from the group consisting of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver

disease, cachexia, obesity, atherosclerosis and arteriosclerosis comprising administering to the subject an amount of the biologically active agent effective to treat the condition; wherein the agent is selected from the group consisting of:

4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid;
Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate;
Ethyl 4-(4-cyclohexylmethoxyphenyl)-4-oxobutanoate;
4-(3-chloro-4-cyclopropylmethoxyphenyl)-4-oxobutanoic acid;
Ethyl 3-(4-benzyloxyphenyl)-3-oxopropanoate;
Ethyl 3-(3-benzyloxyphenyl)-3-oxopropanoate;
Ethyl 3-(2-benzyloxyphenyl)-3-oxopropanoate;
Methyl 3-(3-(2,6-dichlorobenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(4-(4-chlorobenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(3-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(2-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(2-(2-methoxybenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(2-(3-methoxybenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(4-benzyloxy-3-chlorophenyl)-3-oxopropanoate;
Ethyl 3-(4-benzyloxy-3-methoxyphenyl)-3-oxopropanoate;
Ethyl 3-(3-benzyloxy-4-methoxyphenyl)-3-oxopropanoate;

and pharmaceutically acceptable salts thereof.

3. The method of claim 2, wherein the agent is administered orally.
4. The method of claim 2, wherein the subject is a human.
5. The method of claim 4, wherein the agent is administered in an amount from one milligram to four hundred milligrams per day.
6. The method of claim 2, wherein the condition is insulin resistance syndrome or Type II Diabetes.
7. The method of claim 2, wherein the condition is Type 1 Diabetes.

8. The method of claim 2, wherein the treatment reduces a symptom of diabetes or the chances of developing a symptom of diabetes, wherein the symptom is selected from the group consisting of: atherosclerosis, obesity, hypertension, hyperlipidemia, fatty liver disease, nephropathy, neuropathy, retinopathy, foot ulceration and cataracts, associated with diabetes.

9. A pharmaceutical composition for use in the treatment of a condition selected from the group consisting of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis, arteriosclerosis and adapted for oral administration, comprising from one milligram to four hundred milligrams of biologically active agent selected from the group consisting of:

4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid;
Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate;
Ethyl 4-(4-cyclohexylmethoxyphenyl)-4-oxobutanoate;
4-(3-chloro-4-cyclopropylmethoxyphenyl)-4-oxobutanoic acid;
Ethyl 3-(4-benzyloxyphenyl)-3-oxopropanoate;
Ethyl 3-(3-benzyloxyphenyl)-3-oxopropanoate;
Ethyl 3-(2-benzyloxyphenyl)-3-oxopropanoate;
Methyl 3-(3-(2,6-dichlorobenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(4-(4-chlorobenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(3-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(2-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(2-(2-methoxybenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(2-(3-methoxybenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(4-benzyloxy-3-chlorophenyl)-3-oxopropanoate;
Ethyl 3-(4-benzyloxy-3-methoxyphenyl)-3-oxopropanoate;
Ethyl 3-(3-benzyloxy-4-methoxyphenyl)-3-oxopropanoate;

and pharmaceutically acceptable salts thereof.

10. The invention substantially as described above.

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number
WO 2004/041165 A3

(51) International Patent Classification⁷: **A61K 47/00**

(21) International Application Number:
PCT/US2003/034185

(22) International Filing Date: 28 October 2003 (28.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/423,253 1 November 2002 (01.11.2002) US

(71) Applicant (for all designated States except US): **WELL-STAT THERAPEUTICS CORPORATION [US/US];**
930 Clopper Road, Gaithersburg, MD 20878 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HODGE, Kirvin, I.** [US/US]; 8115 Mississippi Road, Laurel, MD 20724 (US). **SHARMA, Shalini** [US/US]; 211 Bristol Downs Drive, Gaithersburg, MD 20878 (US). **von Borstel, Reid W.** [US/US]; 8310 Fox Run, Potomac, MD 20854 (US). **WOLPE, Stephen, D.** [US/US]; 18301 Clear Smoke Road, Boyds, MD 20841 (US).

(74) Agent: **KREISLER, Lewis, J.**; Legal Department, 930 Clopper Road, Gaithersburg, MD 20878 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
3 February 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

(57) Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

WO 2004/041165 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/34185

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 47/00
US CL : 514/778, 866

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 514/778, 866

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
none

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Cas-Online, EAST

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/81340 A2(BRISTOL-MYERS SQUIBB COMPANY) 01 November 2001 (01.11.2001), see page 70, lines 6-24.	1-10

☐

Further documents are listed in the continuation of Box C.

☐

See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

14 November 2004 (14.11.2004)

Date of mailing of the international search report

01 DEC 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Kevin E. Weddington

Telephone No. 571-272-1600